LZAdministrator · Environmental Protection Agency
Zeldin reported 2 sales (est. $16K) and 2 purchases (est. $16K). Holdings included NRSN, DVLT. One transaction was flagged as a late filing.
Last filing: Nov 18, 2025|Transactions: May 13, 2025 – Aug 1, 2025
This total aggregates every source filing listed below. Public trackers focused on a single disclosure may report smaller counts for the same official.
Get an email when Open Cabinet publishes an important update to Lee Zeldin's disclosure record.
No spam. Unsubscribe by replying to any alert.
One dot per disclosed trade, sized by amount. Red = sale, green = purchase.
| Date | Description | Type | Amount | Source |
|---|---|---|---|---|
| Aug 1, 2025 | NeuroSense Therapeutics Ltd. Ordinary SharesLate | Purchase | $1K-$15K | |
| May 16, 2025 | Datavault | Sale | $1K-$15K | |
| May 13, 2025 | NeuroSense Therapeutics Ltd. Ordinary Shares | Sale |
Reviewed financial disclosure documents the Office of Government Ethics has published or recorded for Lee Zeldin. Open Cabinet summarizes listed documents observationally and links to the source PDF where one is publicly available. We do not issue compliance verdicts — that is OGE’s role, not ours.
Published reporting on Lee Zeldin's financial disclosures from major outlets.
AI-assisted search across major outlets.
Zeldin's financial disclosure revealed consulting fees from an investor connected to the Qatari royal family.
E&E reported that Zeldin's OGE financial disclosure and ethics agreement showed $775,000 in salary from Zeldin Strategies, plus LMZ Consulting income and America First Works salary.
Original PDFs from the U.S. Office of Government Ethics. These are the documents Open Cabinet parses.
Source: U.S. Office of Government Ethics, 278-T Periodic Transaction Report. Asset values and transaction amounts are reported in ranges as required by federal law. View original filings
| $1K-$15K |
| May 13, 2025 | Datavault | Purchase | $1K-$15K |
Discloses one transaction: a purchase of NeuroSense Therapeutics (NRSN) on 08/01/2025 in the $1,001-$15,000 range. Filer received a 30-day filing extension; the late notification flag is marked Yes.
Discloses three transactions all dated within May 2025: a sale of NeuroSense Therapeutics (NRSN) on 05/13/2025, plus a paired Datavault (DVLT) purchase on 05/13/2025 and sale on 05/16/2025. Each in the $1,001-$15,000 range and marked No on the 30-day late notification flag.
Self-certification filed roughly three weeks after confirmation, documenting completion of Ethics Agreement obligations including resignations and equity transfers.
Pre-confirmation disclosure for EPA Administrator nominee. Lists outside positions as CEO of Zeldin Strategies, Chairman of Zeldin Cares, President of LMZ Consulting, and director seats at Plymouth Union Public Research, Republican Jewish Coalition, America First Works, and Project Z. Discloses Zeldin Strategies salary of $775,000 plus $1M-$5M in dividends, $144,999 salary from America First Works, casino winnings from Golden Nugget, Venetian, and Atlantis, and numerous honoraria for op-eds placed via CGCN Group, DCI Group, and CRC Advisors.
Commits to resign from Zeldin Strategies upon confirmation and transfer his equity interest to his spouse within 90 days. Commits to place LMZ Consulting into inactive status and resign from America First Works, Zeldin Cares, Plymouth Union Public Research, Republican Jewish Coalition, and Project Z. Lists NeuroSense Therapeutics (NRNS) as a retained stock holding the agency determined did not require divestiture, with recusal commitments.
Source: U.S. Office of Government Ethics public disclosure portal. Document summaries are observational and do not constitute compliance determinations. Compliance with ethics agreements is certified by OGE in their own Compliance Certification document, which is listed above when on file.